Kardiologiya最新文献

{"title":"Registry Study \"HOSTA CHF\": Characterization of the State of the Chronic Heart Failure Treatment Delivery System in Russian Federation Regions: Revealing, Diagnostics, Treatment, Observation.","authors":"F T Ageev, Z N Blankova, O N Svirida, A M Shangina, N V Lazareva, E V Sorokin, A V Pustelenin, A G Ovchinikov, O V Gostishcheva, E B Yarovaya, F N Paleev, S A Boytsov","doi":"10.18087/cardio.2025.5.n2922","DOIUrl":"10.18087/cardio.2025.5.n2922","url":null,"abstract":"<p><p>Among the main priorities of the healthcare system is the problem of chronic heart failure (CHF). It is critically important to assess and reduce the incidence of CHF, improve the treatment of patients with CHF, increase the duration and quality of their life, and reduce the related financial burden. One of the approaches for monitoring the medical care in CHF patients is conducting a large, long-term observational registry study involving multiple medical organizations, with inclusion of the maximum number of patients with documented CHF, assessing continuity, diagnosis and treatment, adherence to treatment, the possibility of algorithmic selection of patients for high-tech medical care and preferential drug provision, morbidity among working/non-working, able-bodied/disabled patients, and assessing the quality of dispensary observation. This article announces a prospective-retrospective observational registry study \"HOSTA CHF\" (Characteristics Of the State of the sysTem of providing cAre to patients with Chronic Heart Failure in the regions of the Russian Federation: detection, diagnosis, treatment, observation), initiated at the Chazov National Medical Research Center of Cardiology.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"3-8"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Echocardiography in the Diagnosis of Pulmonary Hypertension: From Basic to Advanced].","authors":"E G Malev, K N Malikov, N S Goncharova, M A Simakova, E V Karelkina, V A Ryabkov, O M Moiseeva","doi":"10.18087/cardio.2025.5.n2915","DOIUrl":"https://doi.org/10.18087/cardio.2025.5.n2915","url":null,"abstract":"<p><p>Clinical symptoms of pulmonary hypertension (PH) are non-specific and are caused by both high pressure in the pulmonary artery system and progressive right ventricular failure. Instrumental diagnosis of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is complex and requires using invasive and non-invasive imaging methods in the diagnostic algorithm, among which echocardiography (EchoCG) plays an important role. In the initial (screening) evaluation, EchoCG allows assessing the probability of the presence of pulmonary hypertension, the structure and function of the right and left heart chambers, and possible causes of increased pulmonary artery pressure. Echocardiographic imaging is continuously evolving, and measurements made with new methods, such as myocardial strain and 3D imaging, provide access to more information about the right heart chambers in an expert center for the management of patients with PAH and CTEPH. This review describes the parameters and their prognostic value for the diagnosis of PH during both primary (screening) EchoCG and examination in an expert center. Echocardiographic examination of patients with PAH and CTEPH is presented according to their routing stages. Extended EchoCG protocols for primary (screening) examination and examination in an expert center are presented.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"58-69"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Experience of Using the Drug Inclusiran in Patients With an Extremely High Risk Of Developing Cardiovascular Complications in The Acute Period of Myocardial Infarction.","authors":"A V Khripun, E S Godunko, Yu Yu Gridneva, D O Rozhkov, A A Terentyev","doi":"10.18087/cardio.2025.5.n2893","DOIUrl":"https://doi.org/10.18087/cardio.2025.5.n2893","url":null,"abstract":"<p><p>Aim         To evaluate the effect of intensive lipid-lowering therapy (LLT), including inclisiran prescribed in the acute phase of ST-segment elevation myocardial infarction (STEMI), on lipid profile in patients with extremely high risk (EHR) of cardiovascular complications (CVC).Material and methods        This prospective single-center clinical study included 20 patients (mean age 58.45±2.43 years, 75% men) with EHR of CVC and STEMI. All patients were prescribed combination LLT, including inclisiran. Lipid profile parameters were assessed 8±1 days after the initiation of therapy. Statistical analysis was performed with a STATISTICA 13.3 software.Results   Analysis of the lipid-lowering effect of inclisiran showed a significant decrease in total cholesterol from 5.13±0.29 to 2.81±0.26 mmol/l (45.2%; p&lt;0.001) and low-density lipoprotein cholesterol (LDL-C) from 3.59±0.23 to 1.60±0.23 mmol/l (55.4%; p&lt;0.001).Conclusion          The study showed a possibility of achieving statistically and clinically significant reduction in LDL-C in patients with EHR of CVC in the acute period of STEMI with the combination therapy including inclisiran during the inpatient treatment.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"9-15"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship of Serum Chemerin Concentrations with Coronary Slow Flow: A Pathophysiological and Clinical Analysis.","authors":"Aliye Kuyumcu, Mevlüt Serdar Kuyumcu","doi":"10.18087/cardio.2025.5.n2888","DOIUrl":"https://doi.org/10.18087/cardio.2025.5.n2888","url":null,"abstract":"<p><strong>Aim: </strong>Coronary slow flow (CSF) is a condition characterized by below normal blood flow in coronary arteries without significant coronary stenosis. Its pathophysiology is unclear but may involve inflammation, endothelial dysfunction, and microvascular impairment. Chemerin, an inflammation-related adipokine, has been proposed as a potential biomarker in CSF. This study examines the relationship between serum chemerin concentrations and CSF.</p><p><strong>Material and methods: </strong>A total of 100 patients who underwent coronary angiography were classified into CSF (n=50) and normal coronary flow (NCF, n=50) groups. Coronary flow rates were assessed using the Thrombolysis in Myocardial Infarction Frame Count (TFC) method. Serum chemerin concentrations were measured by ELISA. Logistic regression, correlation, and ROC analyses were performed to identify predictors of CSF and to evaluate diagnostic performance.</p><p><strong>Results: </strong>Chemerin concentrations were significantly higher in the CSF group (p&lt;0.001). Logistic regression identified chemerin as an independent CSF predictor (OR=1.097; 95 % CI: 1.022-1.177; p=0.005). Chemerin concentrations correlated positively with TFC (r=0.713, p&lt;0.001). A chemerin cutoff value of 124.5 ng / ml provided 88 % sensitivity and 80 % specificity for CSF diagnosis.</p><p><strong>Conclusion: </strong>Elevated serum chemerin is associated with CSF, suggesting its role in the pathogenesis of CSF and its potential as a diagnostic biomarker. Further research is needed to explore chemerin-targeted therapies in patients with CSF.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"21-27"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Adherence to Treatment of Arterial Hypertension, the Place of Fixed-Dose Combinations].","authors":"E V Akatova, M A Shikina","doi":"10.18087/cardio.2025.5.n2925","DOIUrl":"10.18087/cardio.2025.5.n2925","url":null,"abstract":"<p><p>Cardiovascular diseases occupy one of the leading places in the structure of morbidity, mortality and disability of the population. Arterial hypertension (AH) is the major risk factor for the development of cardiovascular diseases. The problem of insufficient adherence to the treatment of AH remains unresolved in many countries. The administration of fixed combinations is a major way to increase adherence to antihypertensive therapy. In addition, the use of fixed combinations helps to improve the cardiovascular the prognosis in patients with AH by reducing the risk of developing cardiovascular complications.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"52-57"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Aortic Valve Stenosis and Acute Coronary Syndrome. Obvious Answers to Non-Obvious Questions].","authors":"O L Barbarash, V V Kashtalap","doi":"10.18087/cardio.2025.5.n2886","DOIUrl":"10.18087/cardio.2025.5.n2886","url":null,"abstract":"<p><p>The article presents a systematic review focused on clinical features of acute coronary syndrome (ACS) and approaches to its diagnosis in patients with aortic stenosis (AS), as well as approaches to managing the risks of adverse events. The review includes publications from 2000 to 2024. The information in the review by 80% reflects the reports for the recent 5 years. The main databases used in searching for information and writing the review were eLibrary.ru, PubMed, platforms of Nature publishing houses, Springer materials, and PLOS (Public Library of Science). The following keywords were used for the search of publications: aortic stenosis, myocardial infarction, acute coronary syndrome. A total of 105 full-text publications were found; 64 publications best matching the topic of the review were used. The article presents up-to-date data on the complexities of differential diagnosis of decompensated AS and ACS, the general pathogenesis of coronary atherocalcinosis and AS, and promising algorithms for surgical treatment of patients with a combination of AS and various forms of ischemic heart disease (acute and chronic).</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"41-51"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrophysiological Functions of Macrophages are Involved in Atrial Fibrillation.","authors":"Jieqiong Wang, Wenjing Chen, Zewei Sun","doi":"10.18087/cardio.2025.5.n2780","DOIUrl":"https://doi.org/10.18087/cardio.2025.5.n2780","url":null,"abstract":"<p><strong>Aim: </strong>Inflammation, in which macrophages play an important role as immune cells, is closely related to atrial fibrillation (AF). Recent studies have shown that macrophages participate electrical conduction in the heart, thus indicating that they have electrophysiological characteristics. However, whether the electrophysiology of macrophages is associated with AF or not remained unknown. Thus, we investigated the biological function changes in macrophages using patch-clamping after tachypacing to mimic AF.</p><p><strong>Material and methods: </strong>Atrial myocytes and macrophages were cultured. RNA sequencing was performed to investigate the expression change of atrial myocytes after tachypacing. Patch-clamping was conducted to measure the change of APD and ICa,L in macrophages after tachypacing. Rapid atrial stimulation was performed to measure the AF incidence in macrophage-specific CX43 knockout mice.</p><p><strong>Results: </strong>After tachypacing, the time required for 90% repolarization of the action potential and the ICa,L were reduced in macrophages. Furthermore, we found that tachypacing atrial myocytes led to the secretion of Wnt 7a, further inhibiting the expression of CACNA1C in macrophages. Moreover, the knockout of CX43 in macrophages decreased the incidence of AF in a mouse model of chronic inflammation.</p><p><strong>Conclusion: </strong>The electrophysiology of macrophages is related to the development of AF and might be a potential therapeutic target for AF therapy. Prospects for the transfer of laboratory data to the clinic: 1) Regulation of macrophage electrophysiology might be a potential therapeutic target for atrial fibrillation (AF). 2) A Wnt 7a inhibitor could be used to decrease AF incidence. 3) Blocking the interaction between macrophages and atrial myocytes might be a potential therapeutic target for AF.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 5","pages":"35-40"},"PeriodicalIF":0.5,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Body Mass Index and Acute Kidney Injury in Patients who Underwent Coronary Revascularization: A Retrospective Cohort Study from the MIMIC-IV Database.","authors":"Yan Zhang, Xiaofei Jia, Wenxu Fan, Feng Gao, Hang Cui","doi":"10.18087/cardio.2025.4.n2746","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2746","url":null,"abstract":"<p><p>Aim    Acute kidney injury (AKI) remains a common complication of coronary artery revascularization surgery and is associated with adverse outcomes in critically ill surgical patients. Body mass index (BMI) is associated with various diseases. This study aimed to evaluate the association between BMI and the risk of AKI in patients undergoing coronary artery revascularization surgery.Material and methods    In this retrospective cohort study, data were extracted from the Medical Information Mart for Intensive Care (MIMIC) - IV database from 2008 to 2019 for patients undergoing coronary artery revascularization surgery. The outcome was the occurrence of AKI after ICU admission. Covariates were selected using LASSO regression. Univariable and multivariable logistic regression models were utilized to assess the association between BMI and the odds of developing AKI in patients undergoing coronary artery revascularization surgery, with results presented as odds ratios (OR) and 95 % confidence intervals (CI). Subgroup analyses were performed based on age, surgery, anticoagulant use, and the Sequential Organ Failure Assessment (SOFA) score was computed to further explore the association between BMI and AKI.Results    This study included 3017 patients who underwent coronary artery revascularization surgery, of whom 2172 (72.8 %) developed AKI. Increasing BMI was significantly associated with elevated odds of AKI in patients undergoing coronary revascularization (OR = 1.10, 95 % CI: 1.08-1.12), indicating a 10 % increase in AKI risk for each unit increase in BMI, adjusted for demographic variables (age and gender) in Model 1. After further adjustment in Model 2 for significant baseline characteristics including comorbidities (type 2 diabetes, heart failure, malignant tumors, and chronic kidney disease) and ICU scoring systems (SOFA, APS III, SAPS II, OASIS, and CCI), the association remained significant with an 11 % increased risk of AKI per BMI unit increase (OR = 1.11, 95 % CI: 1.08-1.13).Conclusion    BMI may be a promising parameter for assessing the risk of AKI in paty revascularization surgery, providing valuable information for risk stratification and management of ICU patients undergoing such procedures.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"10-15"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Need for Palliative Care for Patients With Chronic Heart Failure].","authors":"V I Shevtsova","doi":"10.18087/cardio.2025.4.n2798","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2798","url":null,"abstract":"<p><p>Aim      To assess the need for palliative medical care (PMC) in patients with chronic heart failure (CHF) depending on their body composition.Material and methods  The study included 298 subjects (115 men and 183 women aged 61 [53; 69] years), who were divided into 5 groups based on their body composition, the presence of obesity and sarcopenia. Kaplan-Meier analysis was used to assess survival, and Cox regression was used to assess the impact of factors.Results Analysis of the need for PMC in patients with CHF depending on body composition showed that patients with sarcopenic obesity had a shorter time to onset of indications for PMC (14.2±2.2 months; 95% confidence interval (CI) 9.8-18.5 months) compared to patients in other groups. The probability of indications for PMC significantly increased with an increase in the ratio of muscle mass index to body mass index (MMI/BMI) by 22.9 times (p&lt;0.001); with an increase in functional class by one by 1.99 times (p&lt;0.001); with an increase in the galectin-3 concentration by 1 ng/ml by 1.02 times (p=0.002); with a decrease in the Barthel index by 0.96 times (p&lt;0.001); and with the presence of sarcopenia by 73% (p&lt;0.001).Conclusion      Patients' need for PMC is influenced by body composition, and patients with sarcopenic obesity have a shorter time to indications for PMC compared to patients with or without isolated body composition disorders.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"42-45"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Possibilities of Predicting Left Ventricular Ejection Fraction 12 Months After ST-Segment Elevation Myocardial Infarction].","authors":"A А Gurbanova, K G Pereverzeva, I E Tishkina","doi":"10.18087/cardio.2025.4.n2823","DOIUrl":"https://doi.org/10.18087/cardio.2025.4.n2823","url":null,"abstract":"<p><p>Aim    To identify predictors and develop a model for prognosis of left ventricular (LV) ejection fraction (EF) 12 months after ST-segment elevation myocardial infarction (STEMI) on electrocardiogram (ECG).Material and methods    This was a prospective registry study of patients admitted within 24 h of STEMI. Concentrations of soluble suppression of tumorigenicity 2, proprotein convertase subtilisin/kexin type 9, N-terminal pro-B-type natriuretic peptide (NTproBNP), high-sensitivity troponin I (TnI), and C-reactive protein were measured. LVEF was determined using the Simpson method at one, 10-12 days, and 12 months after STEMI. The study included 138 patients; after 12 months, LVEF was determined in 112 patients. The patients were divided into groups based on their LVEF: with preserved EF (pLVEF), LVEF ≥50% (n=51); moderately reduced EF (mrLVFE), LVEF 41-49% (n=40); and reduced EF (rLVEF), LVEF ≤40% (n=11).Results     A model for predicting LVEF 12 months after STEMI was constructed using the ordinal regression. The model sensitivity was 88.2% for predicting pLVEF, 71.8% for predicting mrLVEF, and 72.5% for predicting rLVEF. The model specificity was 59.1%. The factors determining LVEF in STEMI patients after 12 months included the formation of postinfarction LV aneurysm, LVEF on days 10-12 after STEMI, the magnitude in mm of ST segment elevation on the ECG upon admission, and the TnI concentration on the first day of STEMI.Conclusions    The obtained model for predicting LVEF 12 months after STEMI allows prognosing LVEF in all its ranges with a sensitivity of more than 70%.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 4","pages":"52-56"},"PeriodicalIF":0.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}